Vcanbio Cell & Gene Engineering Corp., Ltd (SHA:600645)

Market Cap	11.94B
Revenue (ttm)	1.54B
Net Income (ttm)	88.23M
Shares Out	455.90M
EPS (ttm)	0.19
PE Ratio	137.01
Forward PE	70.81
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,997,401
Average Volume	14,417,377
Open	26.06
Previous Close	26.20
Day's Range	25.92 - 26.32
52-Week Range	15.42 - 27.70
Beta	0.40
RSI	65.17
Earnings Date	Aug 29, 2025

About SHA:600645

Vcanbio Cell & Gene Engineering Corp., Ltd, together with its subsidiaries, primarily engages in the preparation and storage of cell detection tests in the People’s Republic of China. The company provides cell test preparation and storage services for umbilical cord blood hematopoietic stem cells, umbilical cord mesenchymal stem cells, placental sub totipotent stem cells, immune cells, adipose stem cells, and dental stem cells. It also provides genetic testing services related to non-invasive prenatal genetic testing during pregnancy, genetic t...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1992
• Employees: 2,014
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600645

Financial Performance

In 2024, SHA:600645's revenue was 1.59 billion, a decrease of -0.27% compared to the previous year's 1.59 billion. Earnings were 100.35 million, a decrease of -5.73%.